Thursday Dec 5
Shire Reports Top-Line Results on OPUS-2, a Phase 3 Study...
Shire plc , the global specialty biopharmaceutical company, today announced top-line results from OPUS-2, a Phase 3 efficacy and safety study of 5.0% lifitegrast ophthalmic solution.
Wed Dec 04, 2013
Shire PLC Files (8-K) Disclosing Unregistered Sale of Equity Securities
Item 3.02. Unregistered Sales of Equity Securities On November 26, 2013 , Shire plc issued an optional redemption notice under the Trust Deed dated May 9, 2007 to holders of the Company's 2.75% Convertible Bonds due 2014 .
Mon Dec 02, 2013
Shire in Generic Adderall XR Deal
Shire plc , announces that its subsidiary Shire US Inc. has entered into an agreement to supply an authorized generic version of its product Adderall XR.
Wed Nov 27, 2013
Inside the deal: Shire's $4.2B acquisition of ViroPharma
While a half-dozen companies kicked ViroPharma's tires this summer, only one ended up making an offer to buy the company.
Tue Nov 26, 2013
Shire PLC - Notice of Redemption of U.S.$1,100,000,000 2.75 per cent
Notice of Redemption of U.S. $1,100,000,000 2.75 per cent. Convertible Bonds due 2014 November 26, 2013 - Shire plc announces that, in accordance with the terms and conditions of its U.S. $1,100,000,000 2.75 per cent.
Thu Nov 21, 2013
FTSE 100 movers: Johnson Matthey tops leaders after results impress
Shares in speciality chemicals company Johnson Matthey leapt to the top of the leaderboard after it reported a robust set of half-year results, powered by a strong performance in Emission Control Technologies ahead of new European legislation and good demand for Process Technologies' products.
Wed Nov 20, 2013
Shire Buying ViroPharma Expected to Add $831 Million in Revenue by 2018
Not only is Shire plc's move to purchase ViroPharma for $50 a share, in a transaction worth a considerable $4.2 billion the largest within the company's history, but it will also boost Shire's six-year growth projection, according to research and consulting firm GlobalData.
Mon Nov 18, 2013
Shire Plc. PT Raised to $165.00 at Jefferies Group
Jefferies Group's price target would suggest a potential upside of 20.99% from the company's current price.
Shire plc's Acquisition of ViroPharma Incorporated Will Add $831 Million In Revenue By 2018, Says
Shire's move to buy ViroPharma for $50 a share, in a transaction worth a considerable $4.2 billion, is the largest in the company's history, and it will significantly boost its six-year growth projection, says an analyst with research and consulting firm GlobalData.
Sun Nov 17, 2013
Research Alert-Shire: Jefferies raises target price
If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links.
Thu Nov 14, 2013
Customer Interaction Solutions
Shareholder Alert: Law Office of Brodsky & Smith, LLC Announces Investigation of ViroPharma, Inc.
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of ViroPharma, Inc. relating to the proposed acquisition by Shire PLC .
Wed Nov 13, 2013
Shire PLC Makes For A Promising Investment
Shire PLC , a Dublin-based biopharmaceutical company, was founded in 1986.. It typically caters to diverse medical needs through research and development, but it also produces, sells and distributes pharmaceutical products.
Viropharma Incorporated Shareholder Alert: Rigrodsky & Long, P.a. Announces Investigation Of Buyout
Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of ViroPharma Incorporated regarding possible breaches of fiduciary duties and other violations of law related to the Company's entry into an agreement to be acquired by Shire plc in a transaction valued at approximately $4.2 billion.
Tue Nov 12, 2013
Sangamo BioSciences, Inc. Announces Presentation Of First...
Sangamo BioSciences, Inc. Announces Presentation Of First Demonstration Of In Vivo Efficacy Of Novel ZFP TherapeuticA For Huntington's Disease /PRNewswire/ -- Sangamo BioSciences, Inc. announced today that positive preclinical data from their joint program with Shire plc to develop a novel ZFP TherapeuticA approach to Huntington's disease were ... (more)
Block & Leviton LLP Investigates ViroPharma Inc. for Possible...
Block & Leviton LLP , a Boston-based law firm representing investors nationwide, has commenced an investigation into possible breaches of fiduciary duty by the Board of Directors of ViroPharma Inc. concerning the proposed acquisition of the Company by U.K.-based company, Shire PLC , in a transaction valued at approximately $4.2 billion.
U.S. Stocks Rest After 5-Week Surge, Shire to Buy ViroPharma for $4.2 Billion
In the year, S&P 500 index has registered the best annual gain since 2003. Nasdaq Composite index is up nearly 30%.
Mon Nov 11, 2013
Shire Buying ViroPharma at a Premium
Nov. 11--Drugmaker Shire P.L.C. said Monday it will pay $4.2 billion for Exton-based ViroPharma.
London Markets: Shire up in London; BSkyB, ITV off after BT soccer deal
The U.K.'s FTSE 100 index inched higher on Monday, with shares of Shire PLC among major advancers after an acquisition, while British Sky Broadcasting Group PLC and ITV PLC declined after rival BT Group won the rights to broadcast Champions League soccer matches.
U.S. Movers: Arkansas Best, Asos, ImmunoGen, Silver Wheaton, Shire
Asos said net loss in the third-quarter narrowed. ImmunoGen signed agreement with Novartis.
Stocks edge mostly higher, keeping Dow at record level; ViroPharma surges on Shire acquisition
The market continued its climb from Friday, when it got a lift from an unexpectedly strong U.S. jobs report.